|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 5. Treatment with the myosin 2 inhibitor blebbistatin decreases actin
recruitment in the YSL and slows the rate of EVL epiboly.(A,B) Bright-field image of an untreated embryo at bud stage
(A) and a (±)-blebbistatin-treated embryo (B). (C)
Quantification of epiboly defects resulting from blebbistatin treatments.
Shown are the percentages of embryos displaying delayed epiboly (80-95%
epiboly) when untreated embryos had reached the 100% epiboly stage. Numbers
are based on two independent experiments. Abbreviations: co, untreated
control; (+)Blb, (+)-blebbistatin treatment; (±)Blb,
(±)-blebbistatin treatment. (D,E) Phalloidin (F-actin)
staining of a control embryo at 75% epiboly and a
(±)-blebbistatin-treated embryo. (F,G) Phalloidin
staining of an untreated embryo at 90% epiboly (F) and
(±)-blebbistatin-treated embryo (G), both injected with a morpholino
against half baked/E-cadherin. Scale bars: in B, 100 µm for A,B;
in E, 50 µm for D,E; in G, 25 µm for F,G.
|
